ELEVATE-TN: 4-Year Follow-up Analysis of Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil for Treatment-Naive CLL

Source: 2021 ASCO Virtual Annual Meeting*
Download Slideset
June 4-8, 2021; Online at https://conferences.asco.org/am
After a median follow-up of approximately 4 years, acalabrutinib-based combination therapy and monotherapy maintained significantly improved PFS and consistent safety profiles vs chemoimmunotherapy in adults with treatment-naive CLL.
Format: Microsoft PowerPoint (.ppt)
File Size: 239 KB
Released: June 6, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings